Active Litigation
Gabapentin Lawsuit Facts
TorHoerman Law is investigating claims for the Gabapentin Lawsuit.
Active Litigation
TorHoerman Law is investigating claims for the Gabapentin Lawsuit.
The Gabapentin lawsuit involves allegations that manufacturers failed to warn patients and healthcare providers about a potential connection between long-term gabapentin use and an increased risk of dementia, mild cognitive impairment, and memory loss.
This page explains the scientific research behind the litigation, the allegations raised in current lawsuits, who may qualify to file a claim, and the current status of the cases.
This content is intended for individuals who took gabapentin, family members of patients diagnosed with cognitive decline, and anyone seeking reliable information about the emerging litigation.
Understanding what researchers have found, what the lawsuits allege, and what evidence may support a claim can help patients make informed decisions about their legal options.
TorHoerman Law is actively investigating the gabapentin lawsuit and we are reviewing claims from those who believe they may qualify.

Gabapentin is one of the most widely prescribed medications in the United States and has long been used as a chronic pain medicine for conditions involving neuropathic pain, epilepsy, and numerous off-label use indications.
Although the drug has been prescribed for decades, recent research has raised questions about whether some adult patients prescribed gabapentin may face a higher dementia risk after prolonged exposure.
A large observational study published in Regional Anesthesia & Pain Medicine found that patients who received repeated gabapentin prescriptions were diagnosed with dementia and mild cognitive impairment at higher rates than comparable patients who did not receive the medication.
The findings have prompted lawsuits alleging that manufacturers knew or should have known about potential cognitive risks but failed to adequately warn patients and healthcare providers.
Researchers continue to study whether gabapentin directly contributes to dementia, and the available evidence does not establish a causal relationship.
Nevertheless, the study has become the foundation for lawsuits involving patients diagnosed with early-onset dementia, memory loss, and other neurocognitive conditions after long-term gabapentin use.
As additional scientific evidence and court filings emerge, the litigation will likely continue to evolve alongside ongoing medical research.
If you or a loved one have been prescribed gabapentin and later developed dementia, mild cognitive impairment, or significant memory loss, you may have legal options, and an experienced attorney can evaluate whether you qualify to pursue a claim.
Contact us today for a free consultation.
Use the chat feature on this page to find out if you qualify for the gabapentin lawsuit.
A Washington woman has filed a lawsuit against Pfizer alleging that gabapentin caused persistent neurological symptoms, including severe headaches and memory loss, that have continued for years after she stopped taking it.
The complaint, filed November 9, 2026 in the U.S. District Court for the Eastern District of Washington, names Pfizer as the only defendant.
The plaintiff was diagnosed with fibromyalgia in September 2020 after about five years of unexplained hip pain. She took gabapentin from around January 2023 until March 2023.
She alleges that debilitating headaches began during use and worsened after she stopped, and that she developed memory problems, including getting lost while driving, missing turns and trouble recalling information.
Her medical records from August 2026 document migraine without aura and memory concerns.
She says the symptoms have left her unable to keep regular employment and have impaired her concentration, decision making and daily functioning.
She seeks more than $75,000 in damages, including lost earning capacity, medical expenses, pain and suffering, diminished quality of life and punitive damages.
A Pennsylvania woman alleges that years of treatment with gabapentin and pregabalin caused severe cognitive problems and early-onset dementia.
Crystal Seifers filed the lawsuit in the Philadelphia Court of Common Pleas in May 2026 against Pfizer Inc., Greenstone LLC, Pharmacia & Upjohn Co. LLC, Pharmacia LLC and Viatris Inc.
According to the complaint, Seifers received at least 94 prescriptions for the medications between approximately 2017 and 2026, including 52 for gabapentin and 42 for pregabalin.
She alleges that prolonged use caused memory loss, difficulty planning and organizing, personality and behavioral changes, visuospatial problems, impaired coordination and early-onset dementia.
The lawsuit claims the defendants failed to adequately investigate or warn patients and physicians about potential long-term neurological risks associated with gabapentinoids. It also alleges that Neurontin was promoted for uses beyond its FDA-approved indications.
Seifers brings claims including negligence, failure to warn, design defect, negligent and fraudulent misrepresentation and breach of warranty. She seeks compensatory damages exceeding $50,000 and punitive damages.
Philadelphia’s Court of Common Pleas has established a mass tort program to coordinate lawsuits alleging that gabapentin and pregabalin caused dementia and other neurocognitive injuries.
The program was established in September, with a case management order filed October 8. Twenty-eight cases involving gabapentin and pregabalin were reportedly part of the coordinated litigation as of October 13.
The lawsuits name Pfizer, Greenstone, Pharmacia & Upjohn, Pharmacia and Viatris and allege that the companies failed to adequately warn patients and doctors about potential dementia and cognitive risks associated with Neurontin and Lyrica.
There is currently no federal multidistrict litigation coordinating these claims. The Philadelphia proceeding provides a centralized state-court process for cases involving similar allegations.
Researchers with Case Western University published a new study warning that gabapentin, one of the most widely prescribed painkillers in the country, may increase the risk of cognitive decline, particularly in younger patients.
The study, published in the journal Regional Anesthesia & Pain Medicine, analyzed health records from more than 26,000 adults with chronic lower back pain between 2004 and 2024, comparing those prescribed gabapentin against similar patients who weren’t.
Patients who received six or more gabapentin prescriptions faced a 29% higher risk of dementia and an 85% higher risk of mild cognitive impairment.
The association grew sharper among younger adults. Those aged 18 to 64 faced roughly 2.1 times the dementia risk and 2.5 times the risk of mild cognitive impairment, and the strongest numbers showed up in the 35 to 49 age group, who faced about 2.4 times the dementia risk and 3.5 times the risk of cognitive impairment.
Researchers also found the risk climbed with more frequent prescriptions, with patients receiving 12 or more facing a 40% higher dementia risk compared to those receiving three to eleven.
Gabapentin has been sold under brand names including Neurontin, Gralise, and Horizant since its original 1993 approval for seizures and chronic pain.
It’s since become widely used off-label for conditions like fibromyalgia, sciatica, anxiety, and alcohol use disorder, with CDC data showing prescriptions have risen more than 200% over the past 15 years.
While the study doesn’t establish that gabapentin directly causes dementia, the findings raise questions about whether manufacturers adequately tested for and warned about cognitive risks tied to long-term use, potentially opening the door to future product liability claims.
Gabapentin lawsuits allege that manufacturers failed to adequately warn patients and healthcare providers about a potential connection between long-term gabapentin use and neurocognitive disorders.
Current lawsuits follow publication of a large observational study that reported higher rates of dementia and mild cognitive impairment among certain patients who received repeated gabapentin prescriptions.
Plaintiffs allege they were prescribed the medication following an initial pain diagnosis and later experienced memory loss, impaired cognitive function, or early-onset dementia.
Although researchers have not established that gabapentin directly causes Alzheimer’s disease or other forms of dementia, recent findings have prompted additional investigation into whether prolonged exposure may contribute to potential cognitive decline in some individuals.
Current lawsuits contend that manufacturers knew or should have known about these potential risks but did not provide adequate warnings.
As additional scientific evidence is evaluated, courts will determine whether the available research supports the claims raised in the litigation.

Current Gabapentin lawsuits generally allege that manufacturers:
The current litigation is based primarily on allegations supported by observational research rather than proof of a direct causal relationship between gabapentin and dementia.
Researchers have emphasized that additional studies are needed to determine whether the reported associations reflect the effects of the medication, underlying medical conditions, or other contributing factors.
Even so, the published findings have become the foundation for lawsuits alleging that manufacturers failed to adequately disclose potential cognitive risks associated with long-term gabapentin use.
Individuals diagnosed with dementia, mild cognitive impairment, or other cognitive disorders after prolonged gabapentin use should consider speaking with an attorney to determine whether they may qualify to pursue a claim.
The scientific evidence supporting current concerns about gabapentin and cognitive decline is centered on a large retrospective study published in the journal Regional Anesthesia & Pain Medicine in 2025.
Researchers analyzed electronic health records from the TriNetX federated health research network, comparing adults with chronic back pain who were prescribed gabapentin to similar patients who did not receive the medication.
The new study evaluated more than 26,000 propensity score-matched patients and examined whether repeated gabapentin prescriptions were associated with later diagnoses of dementia or mild cognitive impairment (MCI).
Although the findings do not establish that gabapentin directly causes dementia, the results support additional research and close monitoring of adult patients prescribed the medication while scientists continue investigating potential cognitive decline.
Researchers reported several important findings:
Although gabapentin is approved by the U.S. Food and Drug Administration to treat partial-onset seizures and postherpetic neuralgia, physicians have prescribed it for a much broader range of conditions for decades.
Prescribing a medication for an unapproved purpose, known as off-label use, is legal when a healthcare provider believes it is medically appropriate for an individual patient.
Gabapentin became increasingly popular as a non-opioid treatment option because it can reduce nerve excitability and may help relieve certain chronic pain conditions and neurological symptoms.
Over time, off-label prescribing far exceeded the drug’s FDA-approved uses, making gabapentin one of the most frequently prescribed medications in the United States.
Many of the patients involved in the current dementia research were prescribed gabapentin for chronic pain conditions rather than its original approved indications.

Common off-label uses for gabapentin include:
Gabapentin affects the central nervous system by binding to voltage-gated calcium channels, reducing the release of certain excitatory neurotransmitters involved in pain signaling and seizure activity.
The U.S. Food and Drug Administration approved the drug in 1993 as an adjunctive treatment for epilepsy and expanded its approved uses in 2002 to include postherpetic neuralgia.

Although gabapentin’s effects on brain signaling are well established, researchers have not reached a consensus that the medication directly causes dementia or other neurodegenerative conditions.
Recent observational research has instead reported an association between repeated gabapentin use and higher rates of mild cognitive impairment and dementia in certain patient populations, prompting additional scientific investigation into the drug’s long-term neurological effects.
The following conditions are among the primary neurocognitive injuries identified in current research and allegations involving prolonged gabapentin use.
Mild cognitive impairment (MCI) is a medical condition characterized by measurable changes in memory, thinking, language, or judgment that are greater than expected with normal aging but are not severe enough to substantially interfere with independent living.
People with MCI generally maintain their ability to perform routine activities, although they may notice increasing difficulty with complex tasks or mental processing.
There is no single test that can diagnose mild cognitive impairment.
Instead, doctors make a clinical diagnosis by considering a patient’s medical history, reported symptoms, neurological examination, cognitive testing, laboratory studies, and, when appropriate, brain imaging while ruling out other possible causes of cognitive decline.
Because MCI can result from a variety of medical, neurological, or psychological factors, a diagnosis does not necessarily mean a person will develop dementia.

People with mild cognitive impairment may experience:
Although many people with MCI continue to live independently, some experience worsening symptoms over time and eventually develop dementia, while others remain stable or even improve if an underlying cause is identified and treated.
Because MCI can be influenced by medications, sleep problems, depression, metabolic issues, neurological disease, and other health factors, clinicians often look closely at a patient’s medication history when cognitive symptoms appear.
In the gabapentin research, MCI matters because it may represent an earlier stage of cognitive change before a dementia diagnosis.
For patients who used gabapentin for months or years, records showing when memory problems began, when MCI was first evaluated, and whether symptoms progressed may be important to understanding the timeline of the alleged injury.
Dementia is a clinical syndrome characterized by progressive impairment of memory, reasoning, language, judgment, and other cognitive abilities severe enough to interfere with independent living and daily function.
Alzheimer’s disease is the most common cause of dementia, although vascular dementia, Lewy body dementia, frontotemporal dementia, and several other neurological disorders can produce similar symptoms.
Unlike normal age-related forgetfulness, dementia affects multiple areas of cognitive function and typically worsens over time as the underlying disease progresses.
There is currently no cure for most forms of dementia, although medications and supportive therapies may help manage symptoms or slow progression in some patients.
Because dementia has many potential causes and risk factors, physicians rely on medical history, cognitive testing, neurological examinations, laboratory studies, and brain imaging to determine the most likely diagnosis.

People living with dementia may experience:
Dementia is the primary injury alleged in current Gabapentin lawsuits because it can permanently affect memory, reasoning, judgment, language, and nearly every aspect of daily function.
While researchers continue investigating whether long-term gabapentin use contributes to an increased dementia risk, the available evidence has prompted closer examination of patients who experienced cognitive decline after years of treatment.
Physicians evaluating dementia must also consider numerous other potential causes, including age, genetics, cardiovascular disease, and other neurological conditions, before determining the most likely explanation for a patient’s symptoms.
As additional research becomes available, scientists hope to better understand whether certain patients face a heightened risk of dementia following prolonged gabapentin exposure and which factors may influence that risk.
Eligibility for a Gabapentin lawsuit depends on several medical and factual considerations, and every claim should be evaluated individually.
Attorneys typically review a person’s prescription history, medical records, cognitive diagnosis, and other potential dementia risk factors before determining whether a case may qualify.
Current intake criteria generally focus on individuals who received six or more prescriptions for gabapentin before developing early-onset dementia or mild cognitive impairment.

Many of the claims under investigation involve chronic pain patients who were prescribed gabapentin for off-label conditions rather than its FDA-approved indications.
A lawyer may also review whether other medical conditions or genetic factors could have contributed to the diagnosis.
Because the litigation remains in its early stages, eligibility criteria may continue to evolve as additional research and court proceedings develop.
Experiencing memory-related gabapentin side effects alone does not necessarily establish a legal claim, but those symptoms may be relevant when considered alongside a later diagnosis of mild cognitive impairment or dementia.
An attorney can review the available evidence and determine whether your medical history is consistent with the allegations raised in current Gabapentin lawsuits.
Medical evidence is one of the most important components of any Gabapentin lawsuit because it helps establish a patient’s prescription history, diagnosis, and progression of cognitive symptoms.
Attorneys typically review medical records to determine when cognitive changes first appeared, how the condition developed over time, and whether other health conditions may have contributed to the diagnosis.
Evidence may also help distinguish the alleged effects of gabapentin from other possible causes of dementia, including underlying medical conditions or other medications known to affect cognitive function.
The strength of a claim often depends on whether the available documentation supports a clear timeline linking prolonged gabapentin use with the onset of cognitive impairment.

Evidence commonly reviewed in a Gabapentin dementia lawsuit includes:
Damages are the financial and personal losses a plaintiff claims resulted from an alleged injury.
In a Gabapentin lawsuit, attorneys evaluate medical records, treatment history, expert opinions, employment information, and other evidence to determine how the alleged cognitive injury has affected a person’s health, finances, and quality of life.
The value of a claim depends on the specific facts of each case, including the severity of the diagnosis, the extent of ongoing care, and the long-term impact on the individual’s independence and earning capacity.
Lawyers use this evidence to calculate damages and advocate for fair compensation through settlement negotiations or, if necessary, at trial.

Potential damages in a Gabapentin lawsuit may include:
Recent scientific research has raised important questions about whether long-term gabapentin use may be associated with dementia, mild cognitive impairment, and other forms of cognitive decline in certain patients.
Although researchers continue to investigate the relationship and have not established that gabapentin directly causes dementia, current lawsuits allege that manufacturers failed to adequately warn about potential long-term cognitive risks.
Individuals diagnosed with cognitive impairment after prolonged gabapentin use may have legal options, and understanding those options begins with a careful review of the available medical evidence.
TorHoerman Law is actively investigating claims involving dementia, memory loss, and other neurocognitive injuries allegedly associated with long-term gabapentin use.

If you or a loved one developed cognitive impairment after taking gabapentin, our attorneys can review your medical history, prescription records, and potential eligibility during a free consultation.
We represent clients on a contingency fee basis, meaning you pay no attorney fees unless we recover compensation on your behalf.
Contact TorHoerman Law today to discuss your potential Gabapentin lawsuit with an experienced product liability attorney.
Gabapentin is a prescription medication classified as an anticonvulsant that is approved by the U.S. Food and Drug Administration to help treat partial-onset seizures and postherpetic neuralgia, a type of nerve pain that can develop after shingles.
Although it was designed as a chemical analog of gamma-aminobutyric acid (GABA), gabapentin does not work by directly activating GABA receptors.
Instead, it binds to alpha-2-delta subunits of voltage-gated calcium channels in the central nervous system, reducing the release of certain excitatory neurotransmitters involved in pain signaling and abnormal nerve activity.
This mechanism helps explain why gabapentin can reduce seizure activity and relieve certain types of nerve pain, while also making it useful for a variety of off-label neurological and pain-related conditions.
Gabapentin is frequently prescribed for medical conditions beyond its FDA-approved indications, a practice known as off-label prescribing.
Off-label use is legal in the United States when a healthcare provider determines that a medication may benefit a patient based on available evidence and clinical judgment.
Because gabapentin affects nerve signaling within the central nervous system, it has been used to manage a variety of neurological, pain-related, and other conditions.
Many patients involved in current gabapentin research and litigation were prescribed the medication for off-label uses rather than its approved indications.
Common off-label uses of gabapentin include:
The gabapentin lawsuit refers to product liability claims alleging that manufacturers failed to adequately warn patients and healthcare providers about a potential connection between long-term gabapentin use and dementia, mild cognitive impairment, and other forms of cognitive decline.
The lawsuits rely in part on a 2025 observational study published in Regional Anesthesia & Pain Medicine, in which researchers found higher rates of dementia and mild cognitive impairment among certain patients who received repeated gabapentin prescriptions than among comparable patients who did not receive the medication.
Plaintiffs contend that manufacturers knew or should have known about potential long-term cognitive risks but did not provide sufficient warnings or update prescribing information accordingly.
Although researchers have not established that gabapentin directly causes dementia, the published findings have become the foundation for current lawsuits.
Individuals who developed early-onset dementia or mild cognitive impairment after prolonged gabapentin use may be eligible to pursue compensation, depending on the facts of their case.
Medical researchers have not established that gabapentin directly causes dementia.
However, one study published in Regional Anesthesia & Pain Medicine reported that certain patients who received repeated gabapentin prescriptions were diagnosed with dementia and mild cognitive impairment at higher rates than comparable patients who did not receive the medication.
Because the study was observational, it identified an association rather than proving that gabapentin caused those conditions.
Additional research will be needed to determine whether a causal relationship exists and to better understand which patients, if any, may be at increased risk.
Researchers have not established that gabapentin directly causes mild cognitive impairment (MCI).
However, a 2025 observational study found that patients who received repeated gabapentin prescriptions were diagnosed with MCI at higher rates than comparable patients who did not receive the medication.
The study reported the strongest association among younger adults ages 35 to 49, although the authors emphasized that their findings do not prove that gabapentin caused the condition.
Additional research is needed to determine whether long-term gabapentin use contributes to MCI or whether other medical factors explain the observed association.
No. The current Gabapentin dementia cases are generally being filed as individual product liability lawsuits rather than as a class action.
Although there have been previous class action and other large-scale lawsuits involving gabapentin, those cases primarily alleged illegal off-label marketing, antitrust violations, and fraudulent business practices, not personal injuries such as dementia or mild cognitive impairment.
Public settlements from gabapentin lawsuits have resulted in significant financial penalties for manufacturers, including a 2004 federal settlement in which a Pfizer subsidiary paid $430 million to resolve criminal and civil allegations related to off-label marketing, as well as later class action settlements totaling hundreds of millions of dollars involving insurers and other third-party payors.
One federal jury also returned a verdict exceeding $142 million after finding that Pfizer’s unlawful promotion of Neurontin caused economic harm to Kaiser Foundation Health Plan, a judgment that was later upheld on appeal.
During that period, gabapentin was widely promoted as a non-addictive alternative to opioids for numerous off-label conditions despite allegations that the manufacturer promoted uses that had not received FDA approval, and more recent attention has focused on reports of dependency and withdrawal in some patients.
Memory loss is a symptom that can occur for many reasons, while dementia is a broader medical syndrome that affects memory as well as other cognitive abilities.
A person may experience memory problems because of stress, medication side effects, sleep disorders, depression, vitamin deficiencies, or other medical conditions without having dementia.
Dementia typically involves progressive impairment of memory, reasoning, judgment, language, and other cognitive functions that eventually interfere with a person’s ability to live independently.
Although memory loss is often one of the earliest signs of dementia, not everyone with memory problems will develop a dementia-related disorder.
Healthcare providers evaluate the pattern, severity, and progression of cognitive symptoms to determine whether memory loss is part of dementia or another underlying condition.
The amount of time you have to file a gabapentin lawsuit depends on the statute of limitations in the state where your claim is filed.
In many states, the filing deadline begins when a person discovers, or reasonably should have discovered, that an injury may be related to a medication rather than on the date the prescription was first taken.
Because dementia and mild cognitive impairment often develop gradually, determining when the statute of limitations begins can be a complex legal and medical issue.
Missing the applicable filing deadline may prevent you from pursuing compensation, regardless of the merits of your claim.
Anyone considering a gabapentin lawsuit should speak with an attorney as soon as possible to understand the deadlines that may apply to their specific case.

Tor Hoerman has represented injured individuals for more than 30 years, with experience spanning individual personal injury cases and nationwide mass tort litigation. His work includes car accidents, catastrophic injuries, product liability claims, and other serious injury cases. Tor has served in court-appointed leadership roles in national litigation and tried cases involving major corporate defendants.
TorHoerman Law’s legal content is researched and written by our editorial team and attorneys for legal accuracy, clarity, and relevance. We rely on statutes, court records, government publications, medical research, and other authoritative sources when applicable. This page provides general legal information and does not constitute legal advice.
TorHoerman Law reviews its legal content for factual accuracy, current information, and relevant legal context before publication and as material developments occur. This article is provided for general informational purposes and does not constitute legal advice. For guidance about a specific case, contact TorHoerman Law.
You can learn more about this topic by visiting any of our Gabapentin Lawsuit pages listed below:
A serious injury can change your life.

TorHoerman Law represents people whose lives have been disrupted by serious injuries, unsafe products, and negligence. Our attorneys handle individual personal injury cases as well as national mass tort lawsuits involving major corporations.
Founded in 2009, our legal team brings more than 100 years of combined experience handling serious injury and complex civil litigation.
Do you believe you’re entitled to compensation?
Use our Instant Case Evaluator to find out in as little as 60 seconds!

In this case, we obtained a verdict of $495 Million for our client’s child who was diagnosed with Necrotizing Enterocolitis after consuming baby formula manufactured by Abbott Laboratories.

In this case, we were able to successfully recover $20 Million for our client after they suffered a Toxic Tort Injury due to chemical exposure.

In this case, we were able to successfully recover $103.8 Million for our client after they suffered a COX-2 Inhibitors Injury.

In this case, we were able to successfully recover $4 Million for our client after they suffered a Traumatic Brain Injury while at daycare.

In this case, we were able to successfully recover $2.8 Million for our client after they suffered an injury due to a Defective Heart Device.
A serious injury can change your life.